Interactions of 172 plant extracts with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8): a study on herb-drug interactions

Hang Lu, Zhiqiang Lu, Xue Li, Gentao Li, Yilin Qiao, Robert P. Borris and Youcai Zhang

School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China

ABSTRACT

Background. Herb-drug interactions (HDIs) resulting from concomitant use of herbal products with clinical drugs may cause adverse reactions. Organic anion transporter 1 (OAT1) and 3 (OAT3) are highly expressed in the kidney and play a key role in the renal elimination of substrate drugs. So far, little is known about the herbal extracts that could modulate OAT1 and OAT3 activities.

Methods. HEK293 cells stably expressing human OAT1 (HEK-OAT1) and OAT3 (HEK-OAT3) were established and characterized. One hundred seventy-two extracts from 37 medicinal and economic plants were prepared. An initial concentration of 5 µg/ml for each extract was used to evaluate their effects on 6-carboxylfluorescein (6-CF) uptake in HEK-OAT1 and HEK-OAT3 cells. Concentration-dependent inhibition studies were conducted for those extracts with more than 50% inhibition to OAT1 and OAT3. The extract of Juncus effusus, a well-known traditional Chinese medicine, was assessed for its effect on the in vivo pharmacokinetic parameters of furosemide, a diuretic drug which is a known substrate of both OAT1 and OAT3.

Results. More than 30% of the plant extracts at the concentration of 5 µg/ml showed strong inhibitory effect on the 6-CF uptake mediated by OAT1 (61 extracts) and OAT3 (55 extracts). Among them, three extracts for OAT1 and fourteen extracts for OAT3 were identified as strong inhibitors with IC50 values being <5 µg/ml. Juncus effusus showed a strong inhibition to OAT3 in vitro, and markedly altered the in vivo pharmacokinetic parameters of furosemide in rats.

Conclusion. The present study identified the potential interactions of medicinal and economic plants with human OAT1 and OAT3, which is helpful to predict and to avoid potential OAT1- and OAT3-mediated HDIs.

INTRODUCTION

Herbal products have increasingly been incorporated into modern health care, with approximately 20% of the population taking herbal products in the United States (Bent, 2008). Consumption of herbal products, particularly when used concomitantly with conventional medications, may increase the risk of severe and potentially even fatal herb-drug...
interactions (HDIs) \cite{Bilgi:10}. It has been reported that about 7\% of the co-users of herbal medicines and prescription medications in the United States had experienced adverse effects \cite{Bush:07}. Therefore, detailed information about possible interactions between herbal products and drugs is needed to prevent HDIs.

Organic anion transporters (human: OATs; rodent: Oats) are members of the solute carrier family SLC22A, and mediate the transport of a wide range of low molecular weight substrates \cite{Nigam:15}. OAT1 and OAT3 are almost exclusively expressed in the kidney, responsible for the renal secretion of a large variety of drugs, including angiotensin-converting-enzyme (ACE) inhibitors, diuretics, antibiotics, and antivirals \cite{Burckhardt:12}. Both Oat1- and Oat3-null mice are viable and fertile \cite{Eraly:06, Sweet:02}, but blood pressure was decreased about 15\% only in Oat3-null mice (but not in Oat1- or Oat2-null mice) \cite{Vallon:08}. Additionally, OAT3 was shown to be required for influenza A virus replication, and an OAT3 inhibitor was shown to be effective in limiting influenza A virus infection \cite{Perwitasari:13}. Therefore, OAT1 and OAT3 are not only drug transporters, but may also be therapeutic targets for hypertension and influenza A infection.

OAT1 and OAT3 have been identified as the targets for potential HDIs. For example, components in the herbal medicine *Salviae miltiorrhizae Radix et Rhizoma* including lithospermic acid, rosmarinic acid, salvianolic acid A, salvianolic acid B and tanshinol have been shown to inhibit human OAT1 and OAT3 \cite{Wang:12}. The anthraquinones in rhubarb have been identified as strong inhibitors to human OAT1 and OAT3 \cite{Ma:14}. However, few studies have been conducted to systematically investigate the interactions of herbal extracts with human OATs. In this study, we examined the effects of 172 extracts from 37 medicinal and economic plants on the function of OAT1 and OAT3, to investigate whether novel HDIs might exist. It must be noted that a number of the plants that we have studied are used as foods or beverages rather than drugs. As such, people consuming them may not realize the potential they represent for interacting with drugs or other herbal products that they are also employing as medicines.

**MATERIALS AND METHODS**

**Drugs and reagents**

Probenecid, furosemide, warfarin and poly-D-Lysine were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 6-Carboxyfluorescein (6-CF) was obtained from Aladdin (Shanghai, China). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and trypsin were purchased from Gibco (Gaithersburg, MD, USA). Hygromycin B was purchased from Solarbio (Beijing, China). BCA protein assay kit was purchased from Cwbio (Beijing, China). Methanol, n-hexane, dichloromethane, and n-butanol were purchased from J&K Chemical (Beijing, China). All other chemicals, unless indicated, were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).

**Plant extracts**

A total of 37 medicinal and economic plants were collected by staff members from the New York Botanical Garden (Mr. Daniel Atha) and the National Herbarium of the Republic of
Georgia (Dr. Manana Khutsishvili) during 2006 at various sites in the Republic of Georgia, Armenia, Azerbaijan, and the United States. Voucher specimens have been prepared and deposited in the National Herbarium of Georgia and the New York Botanical Garden. Each sample was identified by the staff of these herbaria using standard botanical methods. A list of the taxa investigated in the current study and their relative information are presented in Table S1. The detailed preparation method of plant extracts is shown in Fig. S1. Briefly, methanol extracts were prepared from either the entire plant or discrete parts of the plant. Each methanol extract was further fractionated to provide four fractions, namely n-hexane (H), dichloromethane (D), n-butanol (B) and aqueous (A). As a result, a total of 172 plant extracts were prepared, and maintained at −20 °C until use.

**Cloning and expression of human OAT1 and OAT3**

HEK293 cells (bought from Invitrogen, Carlsbad, CA, USA) stably expressing OAT1 and OAT3 were established using the Flp-In expression system (Invitrogen) according to the manufacturer’s protocol as described in a previous publication (Chen et al., 2009). In brief, the cDNAs of OAT1 (GenBank accession number NM_004790) and OAT3 (GenBank accession number NM_004254) were obtained from OriGene (Rockville, MD, USA), and sub-cloned into pcDNA5/FRT (Invitrogen). They were co-transfected with pOG44 into Flp-in-293 cells. Stable cells (HEK-OAT1 and HEK-OAT3) were selected in the presence of hygromycin B (75 µg/ml). Cells were routinely grown in DMEM containing 10% FBS, 1% streptomycin/penicillin and hygromycin B (75 µg/ml) in a humidified incubator at 37 °C and 5% CO₂. The mRNAs of OAT1 and OAT3 in three cell lines were quantified by quantitative real-time PCR. The method and primer sequences are shown in Table S2.

**Uptake assay**

Cell uptake assay was performed as previously described with some modifications (Hsueh et al., 2016). Cells were seeded at a density of 7 × 10⁴ cells per well in poly-D-lysine-coated 96-well culture plates. Transport assays were performed 16-h post seeding in preheated uptake buffer (135 mM NaCl, 5 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 0.8 mM MgSO₄, 28 mM glucose, and 13 mM Hepes, pH 7.2). 6-CF was used as the fluorescent substrate for both hOAT1 and hOAT3 according to a previous study (Duan et al., 2012). The 6-CF alone or 6-CF with different inhibitors (probenecid or plant extracts) was incubated for 4 min in HEK-OAT1 cells and 10 min in HEK-OAT3 cells. Uptake was terminated by adding ice-cold phosphate-buffered saline (PBS), and quickly washed three times with ice-cold PBS. The cells in each well were lysed with 100 µl of 20 mM Tris–HCl containing 0.2% TritonX-100. An aliquot of 50 µl lysate was used to determine fluorescence using a Tecan Infinite M200 (Mannedorf, Switzerland) with excitation and emission wavelengths at 485 and 528 nm, respectively. The protein concentration of the cell lysate was determined using a BCA Protein Assay Kit (Cwbio, Beijing, China). Uptake values were standardized against protein content, and were measured in triplicate.

Uptake kinetics were characterized by measuring the uptake of increasing concentration of 6-CF (0–500 µM) in cells stably expressing hOAT1 (4 min) and hOAT3 (10 min). Michaelis constants were obtained by fitting to the Michaelis–Menten equation.
\[ V = \frac{V_{\text{max}} S}{(K_m + S)}, \] where \( V_{\text{max}} \) is the maximum transport rate, \( S \) is the substrate concentration and \( K_m \) is the substrate concentration reaching half-maximal uptake rate (Graphpad Prism version 5, San Diego, CA, USA).

The fluorescence of each extract in the presence or absence of 6-CF was measured to rule out detection error. Probenecid was loaded into four corners of each 96-well plate, and used as a positive control. The stock solutions of plant extracts were prepared using DMSO with a final concentration of 1 mg/ml. The initial concentration for each extract was set at 5 µg/ml. Every well contained the same concentration of DMSO (0.5%) to eliminate the potential effect of solvent. Uptake of 6-CF (4 µM) was quantified for 4 min for OAT1 and 10 min for OAT3 in the presence or absence of plant extracts with a final concentration of 5 µg/ml. Before the initial screening, the reproducibility of uptake experiments was evaluated. The uptake of 6-CF (4 µM) in HEK-OAT1 and HEK-OAT3 cells were measured in the absence and presence of probenecid (100 µM) in three plates with four repeated wells per uptake assay in each plate. The results demonstrated that the inhibitory effect of probenecid on OAT-mediated 6-CF uptake was reproducible (Fig. S3). Due to the large number of samples, for the initial screening study, each uptake experimental sample was measured in triplicates in the same assay. For those plant extracts showing more than 50% inhibition, the uptake experiments were repeated twice to validate the results.

Those plant extracts showing more than 50% inhibition of 6-CF uptake were selected to carry out concentration-dependent inhibition experiments. To determine IC_{50} (50% inhibitory concentration) values, three-fold serial dilutions of the tested extracts (0–5 µg/ml) and probenecid (0–200 µM) were prepared in triplicate in a 96-well plate and mixed with an equal volume of 6-CF (4 µM). In the experiment, we found that DMSO at concentrations up to 2% had little effect on OAT-mediated 6-CF uptake (Fig. S4). Therefore, the control group contained 0.25% DMSO for the concentration-dependent inhibition experiments. After the uptake was terminated at 4 min and 10 min for OAT1 and OAT3 respectively, intracellular fluorescence was determined as above. IC_{50} values were estimated by non-linear regression analysis, using the following equation:

\[ Y = \frac{100}{(1 + X \cdot \text{HillSlope})/(\text{IC}_{50} \cdot \text{HillSlope})}; \]

where \( X \) is the logarithm of inhibitor concentration; \( Y \) is the normalized response; and HillSlope is the Hill slope factor (Graphpad Prism Version 5; Graphpad, San Diego, CA, USA).

**Pharmacokinetic studies**

Pharmacokinetic study of furosemide was performed according to a previous publication (Ma et al., 2014). Male Sprague–Dawley (SD) rats (200–220 g) were obtained from Vital River Laboratories (Beijing, China), and housed in the certified animal facility at the Institute of Radiation Medicine of the Chinese Academy of Medical Sciences (CAMS, Tianjin, China). All of the experimental protocols and animal handling were performed with the approval of the Animal Use Committee at the CAMS (No. 1202). Rats were acclimated for 1 week in a temperature controlled room (23 ± 2 °C), with a relative humidity of 55 ± 10%. Food and water were supplied ad libitum. The rats were fasted for 12 h before the experiment. For the interaction by *Juncus effusus* extract, a dose of 100 mg/kg of this extract (dissolved in 40% PEG400) was administered to the rats by either oral gavage or tail vein
injection at 5 min before administration of 10 mg/kg FS (dissolved in saline) intravenously through the tail vein. For the control group, a same volume of 40% PEG400 was administered to the rats at 5 min before the injection of a same volume of saline. About 700 µl blood was collected into heparinized tubes via the orbital venous sinus at 2, 5, 10, 15, 30, 60, 90, and 120 min. Plasma sample (250 µl) was pipetted into a microcentrifuge tube, and 1 ml acetonitrile (containing 40 µg/ml warfarin as internal standard) was added. The mixture was vortexed and centrifuged at 20,000 rpm for 15 min. The supernatant was dried in vacuum and then was reconstituted in 200 µL mobile phase for HPLC injection.

**Quantification of furosemide by HPLC-UV**

The concentrations of furosemide were quantified using a modified HPLC method ([Jankowski, Skorek-Jankowska & Lamparczyk, 1997; Ma et al., 2014]). Chromatographic analysis was performed on an Agilent 1260 HPLC system (Agilent Technologies, Santa Clara, CA, USA) consisting of a G1311C Quaternary pump, G1329B autosampler (0.1–100 µL), G1316A column oven (273–333 K), and G1315D Diode Array Detector (190–950 nm). The analytical column was a ZORBAX SB-C18 column (4.6 × 150 mm, 5 µm; Agilent, Santa Clara, CA, USA) with a precolumn. The mobile phase was a mixture of acetonitrile and distilled water (69:31, v/v) with 0.3 M sodium acetate buffer (pH 5.0). The column temperature is 30 °C with a flow rate of 1 ml/min. The injection volume was 10 µl, and the detection wavelength was set at 280 nm.

**Data analysis**

For the pharmacokinetics, five rats per group were used. Data with error bars represent means ± S.D. Pharmacokinetic parameters were calculated using a non-compartmental analysis by using PKSolver ([Zhang et al., 2010]). Data were analyzed with two-tailed unpaired Student’s t-test. The p value for statistical significance was set to be <0.05.

**RESULTS**

**Characterization of OAT1- and OAT3-overexpressing cells**

HEK293 cells stably expressing OAT1 and OAT3 (HEK-OAT1 and HEK-OAT3) were validated by both mRNA expression and uptake function. As shown in Fig. S2, the mRNA expressions of OAT1 and OAT3 were almost undetectable in HEK-EV cells, whereas they are markedly increased in HEK-OAT1 and HEK-OAT3 cells, respectively. Both HEK-OAT1 and HEK-OAT3 cells exhibited a time- and concentration-dependent increase in the uptake of 6-CF (Fig. 1A). The estimated $K_m$ values for the uptake of 6-CF by hOAT1 and hOAT3 were 10.86 ± 0.64 µM and 112.9 ± 14.24 µM, respectively. The $V_{max}$ values of 6-CF uptake for HEK-OAT1 and HEK-OAT3 cells were 168.5 ± 2.27 and 71.89 ± 3.42 pmol/mg protein/min, respectively. Probenecid is a classic inhibitor for OAT1 and OAT3. The estimated IC$_{50}$ value of probenecid was 29.42 µM for OAT1, and 8.662 µM for OAT3 (Fig. 1B). Fluorescence images of cells treated with 6-CF in the presence or absence of probenecid were taken using a fluorescence microscope (Nikon E100; Nikon, Tokyo, Japan). As shown in Fig. 1C, no detectable fluorescence was observed in HEK-EV cells treated with 6-CF. Both HEK-OAT1 and HEK-OAT3 cells treated with 6-CF showed a strong fluorescence, which
Figure 1 Characterization of OAT1- and OAT3-expressing HEK293 cells. (A) Time course and saturation curve of 6-CF uptake in HEK-EV, HEK-OAT1 and HEK-OAT3 cells. Means ± SD of triplicate determination (n = 3) were given. (B) Dose-dependent inhibition of probenecid on 6-CF uptake in HEK-OAT1 and HEK-OAT3 cells. Each data point is the mean of triplicate values (n = 3), and the line represents a best fit of the data using nonlinear regression analysis. (C) Fluorescence images of 6-CF uptake in the absence or presence of probenecid (30 µM) in HEK-EV, HEK-OAT1, and HEK-OAT3 cells.

was almost completely abolished by co-incubating probenecid. Therefore, HEK-OAT1 and HEK-OAT3 cells were successfully established and characterized by functional assay.

Effects of 172 plant extracts on OAT1- and OAT3-mediated 6-CF transport

Among the 172 plant extracts investigated in the initial screening study, 59 extracts (9H, 24D, 18B, and 10A) significantly inhibited the 6-CF uptake in HEK-OAT1 cells, whereas nine extracts (2H, 2B and 5A) significantly increased the OAT1-mediated uptake of 6-CF (Fig. 2 and Table 1). Similarly, 55 extracts (8H, 28D, 16B, and 3A) significantly inhibited
the OAT3-mediated uptake of 6-CF, whereas seven extracts (2B and 5A) increased the 6-CF uptake in HEK-OAT3 cells.

Three hexane extracts (Achillea biebersteinii, Chaerophyllum bulbosum, Symphytum asperum), 17 dichloromethane extracts (Anchusa azurea, Camphorosma lessingii, Chaerophyllum bulbosum, Echium russicum, Elaeagnus orientalis, Glycyrrhiza glabra, Hypericum scabrum, Juncus effusus, Juniperus oblonga (RT), Juniperus oblonga (LF + FR), Melandrium album, Mentha longifolia, Pimpinella peregrina, Polygonum hydropiper, Primula maculata, Ruscus hygrometricus), three dichloromethane/n-butanol extracts (Scrophularia orientalis, Scutellaria orientalis, Solanum dulcamara [ST + RT]), 12 n-butanol extracts (Anchusa azurea, Artocarpus altilis, Chaerophyllum bulbosum, Echium russicum, Glycyrrhiza glabra, Hypericum scabrum, Juniperus oblonga (LF + FR), Mentha longifolia, Scutellaria orientalis, Symphytum asperum, Thymus kotschyanus, Zygophyllum fabago), and one aqueous extract (Thymus kotschyanus) showed inhibitory effects on both OAT1 and OAT3.

**IC$_{50}$ values of plant extracts on OAT1- and OAT3-mediated 6-CF transport**

As shown in Table 1, 18 extracts for OAT1 and 25 extracts for OAT3 showed more than 50% inhibition. These 43 extracts were selected for further concentration-dependent inhibition studies. Some extracts did not show a good concentration-dependent inhibition on 6-CF...
| Botanical name               | Plant part used     | H | OAT1 | OAT3 | D | OAT1 | OAT3 | B | OAT1 | OAT3 | A | OAT1 | OAT3 |
|-----------------------------|---------------------|---|------|------|---|------|------|---|------|------|---|------|------|
| Achillea biebersteinii      | Entire plant        | 50% | 77% | 59% | 62% | 83% | 93% | 84% | 126% |
|                            | Leaf and flower     | 109% | 99% | 88% | 63% | 96% | 89% | 77% | 94%  |
| Ambrosia artemisiifolia     | Root                | 95% | 93% | 66% | 66% | 83% | 91% | 126% | 101% |
|                            | Stem                | 56% | 74% | 58% | 54% | 58% | 61% | 99% | 76%  |
| Anchusa azurea              | Entire plant        | 63% | 97% | 76% | 49% | 58% | 15% | 95% | 50%  |
| Artemocarpus altilis        | Leaf                | 103% | 102% | 78% | 91% | 49% | 52% | 91% | 102% |
| Atraphaxis spinosa          | Entire plant        | 92% | 97% | 46% | 66% | 113% | 125% | 120% | 133% |
| Astracantha microcephala    | Entire plant        | 97% | 80% | 92% | 46% | 97% | 76% | 137% | 121% |
| Buxus hyrcana               | Stem                | 95% | 68% | 84% | 81% | 107% | 125% | 92% | 93%  |
| Caccinia macranthera        | Entire plant        | 93% | 102% | 106% | 66% | 106% | 62% | 109% | 129% |
| Caltha polyphylla           | Entire plant        | 99% | 90% | 96% | 46% | 103% | 77% | 111% | 82%  |
| Camphorosma lessingii       | Entire plant        | 67% | 75% | 37% | 45% | 74% | 105% | 72% | 116% |
| Cardaria boissieri          | Entire plant        | 89% | 123% | 88% | 73% | 87% | 81% | 80% | 104% |
| Chaerophyllum bulbosum      | Entire plant        | 77% | 42% | 80% | 65% | 64% | 67% | 97% | 89%  |
| Crataegus orientalis        | Leaf                | 110% | 94% | 102% | 108% | 119% | 143% | 108% | 132% |
| Echium russicum             | Entire plant        | 117% | 76% | 60% | 53% | 49% | 17% | 108% | 121% |
| Elaeagnus orientalis        | Entire plant        | 84% | 93% | 72% | 69% | 63% | 83% | 84% | 88%  |
| Eremostachys macrophylla    | Entire plant        | 63% | 84% | 69% | 77% | 81% | 89% | 79% | 115% |
| Galium verum                | Entire plant        | 101% | 101% | 90% | 73% | 109% | 82% | 110% | 111% |
| Galanthus tuberosum         | Entire plant        | 120% | 112% | 71% | 79% | 30% | 81% | 97% | 116% |
| Glycyrrhiza glabra          | Entire plant        | 63% | 76% | 38% | 27% | 55% | 53% | 86% | 127% |
| Hypericum androsaemum       | Entire plant        | 97% | 92% | 68% | 80% | 74% | 111% | 117% | 139% |
| Hypericum scarbum           | Entire plant        | 61% | 96% | 73% | 72% | 81% | 65% | 59% | 93%  |
| Juncus effusus              | Stem                | 101% | 92% | 55% | 21% | 96% | 79% | 103% | 96%  |
| Juniperus oblonga           | Leaf and fruit      | 92% | 55% | 57% | 37% | 45% | 26% | 100% | 98%  |
| Mentha longifolia           | Entire plant        | 83% | 84% | 68% | 53% | 80% | 87% | 88% | 99%  |
| Mentha longifolia           | Stem                | 74% | 86% | 80% | 72% | 101% | 104% | 79% | 99%  |
| Pimpinella peregrina        | Entire plant        | 95% | 84% | 75% | 67% | 80% | 50% | 130% | 90%  |
| Polygonum hydropiper        | Entire plant        | 79% | 82% | 40% | 37% | 88% | 89% | 99% | 95%  |
| Primula macrocalyx          | Entire plant        | 84% | 114% | 28% | 37% | 88% | 114% | 118% | 106% |
| Ruscus hyrcanus             | Leaf and fruit      | 89% | 70% | 90% | 107% | 101% | 103% | 82% | 122% |
| Scrophularia orientalis     | Entire plant        | 90% | 83% | 74% | 39% | 124% | 76% | 138% | 94%  |
| Scutellaria orientalis      | Entire plant        | 121% | 82% | 65% | 49% | 48% | 50% | 45% | 94%  |
| Solanum dulcamara           | Stem and root       | 86% | 90% | 80% | 47% | 89% | 97% | 71% | 69%  |
| Stachys lavandulifolia      | Entire plant        | 102% | 90% | 88% | 80% | 111% | 84% | 75% | 115% |
| Symphytum aspernum          | Entire plant        | 54% | 76% | 51% | 39% | 64% | 71% | 36% | 76%  |
| Thymus kotschyanus          | Entire plant        | 44% | 67% | 44% | 35% | 60% | 26% | 82% | 81%  |
| Veratrum lobelianum         | Entire plant        | 104% | 79% | 86% | 73% | 100% | 73% | 92% | 103% |
| Zygophyllum fabago          | Entire plant        | 86% | 73% | 46% | 53% | 60% | 60% | 80% | 86%  |
Figure 3  Dose-dependent inhibition of plant extracts on OAT1- and OAT3-mediated 6-CF uptake. Uptake of 6-CF (4 µM) in HEK-OAT1 and HEK-OAT3 cells were measured in the presence of increasing concentrations of plant extracts (0–5 µg/ml). Each data points is the mean of triplicate values (n = 3) from a typical experiment and represents only the transporter-mediated transport. Means ± SD of triplicate determinations were given. The line represents a best fit of the data using nonlinear regression analysis. The unit for IC50 values was µg/ml.

uptake and thus were excluded from further investigation (Fig. S5). Three extracts (Camphorosma lessingii (D), Geranium tuberosum (B), Polygonum hydropiper (D)) were strong inhibitors for OAT1 with IC50 values being <5 µg/ml (2.441, 2.966, and 1.878 µg/ml, respectively) (Fig. 3A). Fourteen extracts (Anchusa azurea (A and B), Astracantha microcephala (D), Chaerophyllum bulbosum (H), Echium russicum (B), Glycyrrhiza glabra (D), Juncus effusus (D), Juniperus oblonga (LF + FR) (B and D), Mentha longifolia (B), Polygonum hydropiper (D), Primula macrocalyx (D), Thymus kotschyanus (B), Symphytum asperum (B)) were strong inhibitors of OAT3 with IC50 values being <5 µg/ml (Fig. 3B).

Interaction of Juncus effusus (D) with FS in rats
The mean plasma concentration–time profiles of FS in the presence and absence of Juncus effusus (D) in rats is shown in Fig. 4. Pharmacokinetic parameters of FS were summarized in Table 2. Results indicated that pretreatment with Juncus effusus (D) significantly altered the pharmacokinetics of FS in rats. The AUC0-t values of FS were increased by 80% and 55% after oral and intravenous coadministration with Juncus effusus (D), respectively. Therefore, concomitant use of Juncus effusus (D) with substrates of OAT1 and OAT3 should require close monitoring for potential HDIs.

DISCUSSION
Plants are capable of synthesis and accumulation of a high diversity of secondary metabolites (SMs) or natural products (NPs) that are not essential for the actual metabolism or physiology of the plants (Wink, 2008). Many phenolic SMs, such as ellagic acid and caffeic acid, have been shown to be strong inhibitors of OATs (Uwai et al., 2011; Whiley, Sweet & Walle, 2005). Flavonoid SMs, such as morin and silybin, were also demonstrated to interact with
Figure 4 The plasma concentration–time course of FS in rats pretreated with *Juncus effusus* extract. Plasma concentration profile of furosemide in rats after tail vein administration of 10 mg/kg furosemide alone (black line) and furosemide with 5 min pre-treatment of 100 mg/kg *Juncus effusus* extract (red line) by oral gavage (A) and tail vein injection (B). Each data point represents the mean ± S.D. of 4–5 rats.

Table 2 Pharmacokinetic parameters of FS in rats following oral and intravenous administration of FS (10 mg/kg) in the presence and absence of *Juncus effusus* extract (100 mg/kg).

| Parameters                  | FS            | FS + Juncus effusus (oral) | FS + Juncus effusus (intravenous) |
|-----------------------------|---------------|----------------------------|-----------------------------------|
| $t_{1/2}$ (min)             | 107.3 ± 10.4  | 327.2 ± 18.1               | 101.5 ± 10.1                      |
| $C_0$ (µg/ml)               | 181.713.5     | 105.8 ± 10.3               | 115.8 ± 10.8                      |
| AUC$_{0-t}$ (µg/ml×min)     | 4588.967.7    | 8254.7 ± 90.9             | 7108.4 ± 84.3                     |
| AUC$_{0-\infty_{obs}}$ (µg/ml×min) | 10,000.8 ± 100.0 | 33,172.4 ± 182.1        | 12,465.3 ± 111.6                  |
| $V_{z_{obs}}$ (L/kg × $10^{-3}$) | 146.9 ± 12.1  | 123.6 ± 11.1              | 118.2 ± 10.9                      |
| Cl$_{obs}$ (L/min/kg × $10^{-3}$) | 1.0 ± 1.0     | 0.4 ± 0.6                  | 0.8 ± 0.9                         |

OATs. Additionally, a recent study reported that several anthraquinones from rhubarb were strong inhibitors of human OATs (*Ma et al., 2014*). Although OATs are present in various tissues, the investigation of DDIs attributable to OAT inhibition has so far concentrated on the kidney. In particular, OAT1 and OAT3, which are highly expressed in the kidney, have been shown to be involved in several DDIs (*Lepist & Ray, 2012*) (*Motohashi et al., 2002*).
So far, few studies have been conducted to elucidate the interactions of herbal extracts with OAT1 and OAT3.

In the present study, 172 extracts from 37 medicinal and economic plants were screened for the effect on OAT1- and OAT3-mediated transport. These plants grow in different parts of the world, and are frequently consumed as herbal medicine, fruits, vegetables, and drinks (Table 1). Among the 172 extracts screened, 59 plant extracts showed an inhibition to OAT1, and 55 plant extracts showed an inhibition to OAT3. OAT3 shares a 51% homology to OAT1 (Cha et al., 2001). Therefore, it is not surprisingly that 33 extracts were able to inhibit both OAT1 and OAT3.

Concentration-dependent inhibition of 6-CF uptake was further conducted for 45 plant extracts with more than 50% inhibition to OATs. Three extracts were identified as strong inhibitors of OAT1 with IC$_{50}$ values being <5 µg/ml. Geranium tuberosum (B) was the strongest inhibitor for OAT1, with IC$_{50}$ value being 1.878 µg/ml (Table 1). Camphorosma lessingii (D) and Polygonum hydropiper (D) also markedly inhibited OAT1. Geranium tuberosum has been used as folk medicine to treat fever, tonsillitis, cough, urticaria, dysentery, kidney pain, and gastrointestinal ailments (Calzada et al., 1999). Camphorosma lessingii is used in Central Asia externally to treat fungal skin diseases and internally to treat rheumatism (Takeuchi et al., 1977). Polygonum hydropiper has historically been used to treat several diseases, such as diarrhea, piles, bleeding, and parasitic worms, and colic pain (Xiao et al., 2016). Our data suggest that concomitant use of these three herbs may increase the risk of HDIs with OAT1 substrate drugs.

Fourteen extracts showed a strong inhibition to OAT3 with IC$_{50}$ values being <5 µg/ml. Anchusa azurea is widely distributed in the Mediterranean region, and has shown antitussive and anti-inflammatory properties (Kuruuzum-Uz et al., 2012). Astracantha microcephala and Chaerophyllum bulbosum are used in the food industry. Echium russicum is a rare plant growing in central and southeastern Europe, and has shown antioxidant and antimicrobial activities (Niciforovic et al., 2010). Glycyrrhiza glabra is the source of licorice which has been widely used in tobacco and food industry (Arora et al., 2016). Juncus effusus is a well-known traditional Chinese medicine used as a sedative, anxiolytic and antipyretic to treat fidgetiness and insomnia (Ma et al., 2015). Juniperus oblonga is a medicinal plant with diuretic and antiscorbutic effects (Pisarev et al., 2011). Mentha longifolia is widely used in traditional medicine to treat many gastrointestinal disorders such as abdominal pain, diarrhea, ulcers, and gut spasm (Murad, Abdallah & Ali, 2016). Primula macrocalyx has been used as a kind of spice due to its peppery taste. Symphytum asperum has demonstrated antioxidant and anti-inflammatory properties (Barthomeuf et al., 2001). Thymus kotschyanus has been traditionally implemented in the treatment of wounds, throat and gum infections and gastrointestinal disorder (Rasooli & Mirmostafa, 2003). Our data suggest that potential HDIs might exist when consuming these herbs with OAT3 substrate drugs.

Although the in vitro data suggest a potential HDI of these extracts, the in vivo environment is more complex. Furosemide, a loop or high-ceiling diuretic, is eliminated mainly by renal excretion in which OAT1 and three play major roles (Brandoni et al., 2006). The in vitro study showed that Juncus effusus (D) was a strong inhibitor of OAT3 with IC$_{50}$ value being 1.21 µg/ml, and also slightly inhibited OAT1. In the preliminary study, we found...
that 100 mg/kg of *Juncus effusus* (D) did not cause any obvious toxic response in mice or rats. Both oral and intravenous co-administration of *Juncus effusus* (D) markedly increased the AUC$_{0-t}$ of FS in rats. Therefore, consideration must be given to the potential clinical interaction of *Juncus effusus* (D) with drug substrates of OATs.

**CONCLUSION**

In summary, we have investigated the inhibitory effects of 172 plant extracts from 37 medicinal plants on OAT1 and OAT3 *in vitro*, and identified four strong inhibitors for OAT1 and 14 strong inhibitors for OAT3. The *in vivo* study showed that *Juncus effusus* markedly altered the pharmacokinetics of FS. It is worthwhile to note that a number of the plants in the present study are used as foods or beverages rather than drugs, and people consuming them may not realize the potential HDIs. The future studies will focus on the isolation and characterization of the active ingredients responsible for the inhibitory effects of these extracts. Given the important physiological and pharmacological role of OATs, the information obtained in this study will not only help to prevent the potential HDIs, but also provide a mechanistic view about the therapeutic applications of the herbs.

**ACKNOWLEDGEMENTS**

The authors gratefully acknowledge Dr. Manana Khutsishvili of the National Herbarium of Georgia (Tbilisi, Georgia), Mr. Daniel Atha of the New York Botanical Garden (Bronx, NY, USA) and Dr. Norman Arancon of the University of Hawaii at Hilo (Hilo, HI, USA) for help in collecting and identifying the plant materials. The authors also thank Xue Wang for repeating the uptake experiment to confirm the effect of DMSO on OAT3-mediated 6-CF uptake.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**

This project was supported by the National Natural Science Foundation of China (No. 81673523). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**

The following grant information was disclosed by the authors:
National Natural Science Foundation of China: No. 81673523.

**Competing Interests**

The authors declare there are no competing interests.

**Author Contributions**

- Hang Lu performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Zhiqiang Lu and Gentao Li performed the experiments, reviewed drafts of the paper.
• Xue Li and Yilin Qiao performed the experiments, contributed reagents/materials/analysis tools, reviewed drafts of the paper.
• Robert P. Borris conceived and designed the experiments, contributed reagents/materials/analysis tools, reviewed drafts of the paper.
• Youcai Zhang conceived and designed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

Animal Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

All of the experimental protocols and animal handling were performed with the approval of the Animal Use Committee at the Institute of Radiation Medicine of the Chinese Academy of Medical Sciences (CAMS, Tianjin, China) (No. 1202).

Data Availability
The following information was supplied regarding data availability:

The raw data has been supplied as Supplementary File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.3333#supplemental-information.

REFERENCES

Arora P, Wani ZA, Nalli Y, Ali A, Riyaz-Ul-Hassan S. 2016. Antimicrobial potential of thiodiketopiperazine derivatives produced by phoma sp., an endophyte of glycyrrhiza glabra linn. Microbial Ecology 72:802–812 DOI 10.1007/s00248-016-0805-x.

Barthomeuf CM, Debiton E, Barbakadze VV, Kemertelidze EP. 2001. Evaluation of the dietetic and therapeutic potential of a high molecular weight hydroxycinnamate-derived polymer from Symphytum asperum Lepech. Regarding its antioxidant, antiiliperoxidant, antiinflammatory, and cytotoxic properties. Journal of Agricultural and Food Chemistry 49:3942–3946 DOI 10.1021/jf010189d.

Bent S. 2008. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. Journal of General Internal Medicine 23:854–859 DOI 10.1007/s11606-008-0632-y.

Bilgi N, Bell K, Ananthakrishnan AN, Atallah E. 2010. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. The Annals of Pharmacotherapy 44:926–928 DOI 10.1345/aph.1M715.

Brandoni A, Villar SR, Picena JC, Anzai N, Endou H, Torres AM. 2006. Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction. Hepatology 43:1092–1100 DOI 10.1002/hep.21142.

Burckhardt G. 2012. Drug transport by Organic Anion Transporters (OATs). Pharmacology and Therapeutics 136:106–130 DOI 10.1016/j.pharmthera.2012.07.010.
Bush TM, Rayburn KS, Holloway SW, Sanchez-Yamamoto DS, Allen BL, Lam T, So BK, Tran de H, Greyber ER, Kantor S, Roth LW. 2007. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. *Alternative Therapies in Health and Medicine* 13:30–35.

Calzada F, Cerda-Garcia-Rojas CM, Meckes M, Cedillo-Rivera R, Bye R, Mata R. 1999. Geranins A and B, new antiprotozoal A-type proanthocyanidins from *Geranium niveum*. *Journal of Natural Products* 62:705–709 DOI 10.1021/np980467b.

Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. *Molecular Pharmacology* 59:1277–1286.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. *Pharmacogenet Genomics* 19:497–504 DOI 10.1097/FPC.0b013e32832cc7e9.

Duan P, Li S, Ai N, Hu L, Welsh WJ, You G. 2012. Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. *Molecular Pharmaceutics* 9:3340–3346 DOI 10.1021/mp300365t.

Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. 2006. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. *Journal of Biological Chemistry* 281:5072–5083 DOI 10.1074/jbc.M508050200.

Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L, Huang SM, Giacomini KM. 2016. Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. *Molecular Pharmaceutics* 13:3130–3140 DOI 10.1021/acs.molpharmaceut.6b00332.

Jankowski A, Skorek-Jankowska A, Lamparczyk H. 1997. Determination and pharmacokinetics of a furosemide-amiloride drug combination. *Journal of Chromatography B* 693:383–391 DOI 10.1016/S0378-4347(97)00055-8.

Kuruuzum-Uz A, Suleyman H, Cadirci E, Guvenalp Z, Demirezer LO. 2012. Investigation on anti-inflammatory and antiulcer activities of Anchusa azurea extracts and their major constituent rosmarinic acid. *Zeitschrift für Naturforschung C* 67:360–366 DOI 10.5560/ZNC.2012.67c0360.

Lepist EI, Ray AS. 2012. Renal drug-drug interactions: what we have learned and where we are going. *Expert Opinion on Drug Metabolism & Toxicology* 8:433–448 DOI 10.1517/17425255.2012.667401.

Ma W, Liu F, Ding YY, Zhang Y, Li N. 2015. Four new phenanthrenoid dimers from Juncus effusus L. with cytotoxic and anti-inflammatory activities. *Fitoterapia* 105:83–88 DOI 10.1016/j.fitote.2015.06.006.

Ma L, Zhao L, Hu H, Qin Y, Bian Y, Jiang H, Zhou H, Yu L, Zeng S. 2014. Interaction of five anthraquinones from rhubarb with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) and drug-drug interaction in rats. *Journal of Ethnopharmacology* 153:864–871 DOI 10.1016/j.jep.2014.03.055.
Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K. 2002. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. Journal of the American Society of Nephrology 13:866–874.

Murad HA, Abdallah HM, Ali SS. 2016. Mentha longifolia protects against acetic-acid induced colitis in rats. Journal of Ethnopharmacology 190:354–361 DOI 10.1016/j.jep.2016.06.016.

Niciforovic N, Mihailovic V, Maskovic P, Solujic S, Stojkovic A, Muratspahic D. 2010. Antioxidant activity of selected plant species; potential new sources of natural antioxidants. Food and Chemical Toxicology 48:3125–3130 DOI 10.1016/j.fct.2010.08.007.

Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, Bhatnagar V, Wu W. 2015. The organic anion transporter (OAT) family: a systems biology perspective. Physiological Reviews 95:83–123 DOI 10.1152/physrev.00025.2013.

Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA. 2013. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrobial Agents and Chemotherapy 57:475–483 DOI 10.1128/AAC.01532-12.

Pisarev DI, Novikov OO, Novikova MY, Zhilyakova ET. 2011. Flavonoid composition of Juniperus oblonga Bieb. Bulletin of Experimental Biology and Medicine 150:714–717 DOI 10.1007/s10517-011-1231-1.

Rasooli I, Mirmostafa SA. 2003. Bacterial susceptibility to and chemical composition of essential oils from Thymus kotschyanus and Thymus persicus. Journal of Agricultural and Food Chemistry 51:2200–2205 DOI 10.1021/jf0261755.

Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. 2002. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. Journal of Biological Chemistry 277:26934–26943 DOI 10.1074/jbc.M203803200.

Takeuchi T, Nakagawa Y, Ogawa M, Kawachi T, Sugimura T. 1977. Immunoreactivities of alpha-amylase of humans and rats. Clinica Chimica Acta 77:203–206 DOI 10.1016/0009-8981(77)90028-6.

Uwai Y, Ozeki Y, Isaka T, Honjo H, Iwamoto K. 2011. Inhibitory effect of caffeic acid on human organic anion transporters hOAT1 and hOAT3: a novel candidate for food-drug interaction. Drug Metabolism and Pharmacokinetics 26:486–493 DOI 10.2133/dmpk.DMPK-11-RG-020.

Vallon V, Eraly SA, Wikoff WR, Rieg T, Kaler G, Truong DM, Ahn SY, Mahapatra NR, Mahata SK, Gangoiti JA, Wu W, Barshop BA, Siudak G, Nigam SK. 2008. Organic anion transporter 3 contributes to the regulation of blood pressure. Journal of the American Society of Nephrology 19:1732–1740 DOI 10.1681/ASN.2008020180.

Wang L, Sweet DH. 2012. Active hydrophilic components of the medicinal herb salvia miltiorrhiza (Danshen) potently inhibit organic anion transporters 1 (Slc22a6) and 3 (Slc22a8). Evidence-Based Complementary and Alternative Medicine 2012:872458–872465 DOI 10.1155/2012/872458.

Lu et al. (2017), PeerJ, DOI 10.7717/peerj.3333
Whitley AC, Sweet DH, Walle T. 2005. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. *Drug Metabolism and Disposition: The Biological Fate of Chemicals* **33**:1097–1100 DOI 10.1124/dmd.105.004275.

Wink M. 2008. Evolutionary advantage and molecular modes of action of multi-component mixtures used in phytomedicine. *Current Drug Metabolism* **9**:996–1009 DOI 10.2174/138920008786927794.

Xiao H, Rao Ravu R, Tekwani BL, Li W, Liu WB, Jacob MR, Khan SI, Cai X, Peng CY, Khan IA, Li XC, Wang W. 2016. Biological evaluation of phytoconstituents from Polygonum hydropiper. *Natural Product Research* Epub ahead of print Dec 21 2016 DOI 10.1080/14786419.2016.1269094.

Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. *Computer Methods and Programs in Biomedicine* **99**:306–314 DOI 10.1016/j.cmpb.2010.01.007.